SA
Go ProLog In
GLUE
OverviewIntelligenceChart

Analyst Sentiment

Wall St. Consensus
Buy
8 analysts·Limited coverage
72
Score
7 Buy (88%)1 Hold (13%)0 Sell (-1%)
Rating Breakdown
Strong Buy
00%
Buy
788%
Hold
113%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$22.00
+21.2%
Consensus
$34.00
+87.3%
Bull
$37.00
+103.9%
12-Month Target Range8 analysts
$22.00$34.00$37.00
Current $18.15Consensus
Current Price
$18.15
Upside to Consensus
$15.85

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+30.94%
EPS—
FY2028
Rev-61.78%
EPS—
FY2029
Rev+417.48%
EPS—

Earnings Surprises

Recent Analyst Actions

Jan 14, 2026Piper Sandler
Monte Rosa Therapeutics price target raised to $37 from $27.50 at Piper Sandler
Target:$37.00
+54.2%from $23.99
Jan 7, 2026Jefferies
Monte Rosa Therapeutics price target raised to $31 from $22 at Jefferies
Target:$31.00
+33.1%from $23.29
Jan 7, 2026Wedbush
Monte Rosa Therapeutics price target raised to $37 from $26 at Wedbush
Target:$37.00
+52.2%from $24.31
Dec 17, 2025Jefferies
Monte Rosa Therapeutics (GLUE) PT Raised to $22 at Jefferies
Target:$22.00
+17.9%from $18.66
Dec 16, 2025Wells Fargo
Monte Rosa Therapeutics upgraded to Overweight from Equal Weight at Wells Fargo
Target:$22.00
+33.7%from $16.45

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance